CurrentCapital BluecrossPolicy AHS F2019 Flow Cytometry

Flow Cytometry

Covers clinical indications, coverage limitations, coding/reimbursement guidance, and scientific background for flow cytometry testing (immunophenotyping, cell enumeration, DNA ploidy and S-phase fraction) for Capital Bluecross members.

Policy Summary

PayerCapital Bluecross

PolicyFlow Cytometry

Policy CodePolicy AHS F2019 Flow Cytometry

Change TypeNo material changes

Effective DateJul 1, 2025

Next Review DateJul 1, 2025

Key ActionOrder flow cytometry immunophenotyping with a specific clinical indication and select appropriate CPT codes while observing unit limits and mutually exclusive code combinations.

SourceLink

POLICY UPDATE CHANGES

No material clinical or coverage changes in this revision.

88184-88189; 86355-86367Procedure code groups

Not coveredDNA ploidy/SPF stance

MultipleCovered indications

SpecifiedUnit limits

Coverage Criteria — Flow Cytometry

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

inv-01: Covered Indications — Flow cytometry immunophenotyping

Flow cytometry immunophenotyping of cell surface markers meets coverage criteria for any of the following:

Covered clinical indications: a) Cytopenias, lymphomas, leukemia, myeloproliferative and lymphoproliferative disorders, or myelodysplastic syndrome; b) B-cell monitoring for immunosuppressive disorders; c) T-cell monitoring for HIV infection and AIDS; d) Mast cell neoplasms; e) Paroxysmal nocturnal hemoglobinuria (PNH); f) Preoperative or postoperative monitoring for organ transplantation; g) Plasma cell disorders; h) Primary immunodeficiencies (PIDs); i) Primary platelet disorders (non-neoplastic); j) Red cell and white cell disorders (non-neoplastic).

inv-02: Reimbursement and coding limitations for immunophenotyping

When used for assessment of potential hematolymphoid neoplasia, coding and unit limits apply:

Coding/unit logic: Use CPT codes 88184-88189 for immunophenotyping; code 88184 for the first marker per specimen (reimbursable up to a maximum of two units per date of service); code 88185 for each additional marker (reimbursable up to a maximum of 35 units per date of service). In patients with a neoplasm with an established immunophenotype, subsequent testing should be limited to diagnostically relevant markers. Codes 88187, 88188, and 88189 should not be used together for a single specimen in any combination; these codes are reimbursed at one unit per specimen, up to two specimens per date of service. Codes 88187-88189 must not be used in conjunction with cell enumeration codes 86355, 86356, 86357, 86359, 86360, 86361, or 86367. Use codes 86355, 86357, 86359, 86360, 86361, or 86367 for cell enumeration; these are reimbursable as single units only.

Observe unit limits and mutually exclusive code combinations as specified.

inv-03: Supported clinical indications

Covered when testing aligns with guideline-supported clinical indications and panel composition

General indications: Flow cytometry is indicated for evaluation of cytopenias, elevated leukocyte count, atypical cells or blasts, body fluids, plasmacytosis or monoclonal gammopathy, organomegaly, tissue masses, and certain monitoring indications.

Selection of reagents for initial evaluation should be based on specimen type, clinical information, and cell morphology; initial panels range from 4 to 12 reagents.

Acute leukemia initial workup: Obtain sufficient samples and perform flow cytometric immunophenotyping with a panel adequate to distinguish B-ALL and other acute leukemias; perform conventional cytogenetics and appropriate molecular/FISH testing as part of the initial diagnostic workup; ensure panels are comprehensive enough to allow subsequent detection of minimal residual disease.

CAP/ASH 2016 joint guideline — multiple strong recommendations.

ERIC/ESCCA marker selection: When applying CLL harmonization guidance, use markers recommended/required per ERIC/ESCCA harmonisation; marker sets reviewed include up to 35 markers with 'required' markers defined by consensus thresholds.

Flow cytometry can measure cellular DNA content (ploidy) and the proportion of cells in S-phase (S-phase fraction, SPF). However, measurement of flow cytometry–derived DNA content or % S-phase for prognostic or therapeutic purposes in the routine clinical management of cancers does not meet coverage criteria.

Major oncology and pathology guideline groups have concluded that flow-cytometric DNA ploidy and S-phase/proliferation analysis are not supported for routine prognostic or management decisions in several solid tumors. Specifically, ASCO states that DNA ploidy and % S-phase should not be used to determine prognosis of early-stage colorectal cancer and considers these assays experimental in this context; ASCO also found insufficient evidence to support routine use of DNA/ploidy in breast cancer management. The NCCN and ISGyP guidance likewise do not endorse routine use of cell proliferation (S-phase) or ploidy analysis for management of breast, lung, or endometrial cancers given limited and inconsistent evidence.

The policy classifies routine use of flow cytometry–derived DNA ploidy or S-phase fraction for prognostic or therapeutic cancer management as not covered due to insufficient published evidence to establish clinical utility for routine care.

Because the published evidence is inconsistent and guideline panels characterize DNA ploidy and S-phase analysis as lacking sufficient validation for routine care, the policy considers their routine prognostic use in certain cancers (for example, early-stage colorectal cancer, breast cancer, and endometrial carcinoma) to be experimental or unsupported for standard clinical management.

Covered Indications and Panel Guidance

inv-27: Immunophenotyping for hematologic disorders and monitoring (cytopenias, lymphoma/leukemia, MPN/MDS, PIDs, PNH, transplant monitoring, plasma cell disorders, primary platelet and RBC/WBC disorders)

Immunophenotyping is covered for hematologic disorders and monitoring in the following clinical contexts:

Hematologic disorders and monitoring: Immunophenotyping for cytopenias; lymphoma and leukemia evaluation and monitoring; myeloproliferative neoplasms (MPN) and myelodysplastic syndromes (MDS); primary immunodeficiencies (PIDs); paroxysmal nocturnal hemoglobinuria (PNH); pre- and post-transplant monitoring; plasma cell disorders; primary platelet disorders (non-neoplastic); primary red cell and white cell disorders (non-neoplastic).

Order panels appropriate to the clinical indication and specimen type.

inv-28: Hematolymphoid neoplasia evaluation (initial and secondary panels), acute leukemia diagnostic workup including MRD monitoring, platelet function and platelet disorder evaluation.

Panel composition and test selection should follow established guideline recommendations and be tailored to specimen type, clinical information, and morphology:

Panel composition principle: Selection of reagents for initial and secondary panels should be based on specimen type (peripheral blood, bone marrow, tissue, or body fluids), clinical information, and cell morphology; initial panels typically include 4–12 reagents and secondary panels 5–23 reagents.

Bethesda 2006 consensus guidance.

Acute leukemia diagnostic workup and MRD monitoring: For suspected or confirmed acute leukemia, obtain sufficient samples and perform flow cytometric immunophenotyping as part of initial workup alongside conventional cytogenetics and molecular/FISH testing; ensure flow cytometry is sufficiently comprehensive to permit later minimal residual disease (MRD) detection.

CAP/ASH 2016 recommendations (strong).

Example initial panels: B-cell panel: CD5, CD10, CD19, CD20, CD45, kappa, lambda; T-cell/NK panel: CD2, CD3, CD4, CD5, CD7, CD8, CD45, CD56; Myelomonocytic panel: CD7, CD13, CD14, CD15, CD16, CD33, CD34, CD45, CD56, CD117, HLA-DR; Plasma cell panel: CD19, CD38, CD45, CD56.

Markers listed from Bethesda 2006 for initial evaluation.

Platelet disorder evaluation: Use flow cytometry per ISTH recommendations for inherited/acquired platelet glycoprotein deficiencies, platelet activation pathway defects, alpha granule secretion defects, GPIIb macrothrombocytopenia, platelet activation assessment in prothrombotic states, pharmacodynamic monitoring of P2Y12 antagonists, and immature platelet fraction determination.

ISTH SSC Subcommittee guidance.

Coding and Reimbursement Guidance

Flow cytometry immunophenotyping CPTsCPTCovered

88184	Flow cytometry; first marker per specimen
88185	Flow cytometry; each additional marker
88187	Flow cytometry; cell population separated (reimbursed one unit per specimen, up to two specimens)
88188	Flow cytometry; interpretation; 9 to 15 markers
88189	Flow cytometry; interpretation; 16 or more markers

Cell enumeration codes (use instead of some 8818x combinations)CPTCovered

86355	Cell enumeration (flow cytometry)
86356	Cell enumeration (mononuclear cell antigen, quantitative)
86357	Cell enumeration (natural killer (NK) cells, total count)
86359	Cell enumeration
86360	Cell enumeration
86361	Cell enumeration (T cells; absolute CD4 count)
86367	Cell enumeration (stem cells, e.g., CD34 total count)

Applicable CPT/HCPCS CodesCPT

86355	B cells, total count.
86356	Mononuclear cell antigen, quantitative (eg, flow cytometry), not otherwise specified, each antigen.
86357	Natural killer (NK) cells, total count.
86359	Icells; total count.
86360	.
86361	Tcells; absolute CD4 count.
86367	Stem cells (ie CD34) total count.
88182	Flow cytometry - cell cycle or DNA analysis.
88184	Flow cytometry, cell surface, cytoplasmic; or nuclear marker, technical component only; first marker.
88185	Flow cytometry, cell surface, cytoplasmic, or nuclear marker; technical component only; each additional marker.

1–10 of 12

1/2

inv-11: Maximum units for CPT 88184

Maximum reimbursable unitsCPT 88184 (first marker, per specimen) is reimbursable up to a maximum of two units per date of service.

Usage contextUse 88184 to report the first marker tested on a specimen; additional markers use 88185.

Billing periodUnit limit applies per date of service.

inv-12: Maximum units for CPT 88185

Maximum reimbursable unitsCPT 88185 (each additional marker) is reimbursable up to a maximum of 35 units per date of service.

Use relationshipReport 88185 for each marker beyond the first marker reported with 88184.

Billing periodUnit limit applies per date of service.

inv-13: Usage restriction — 88187-88189 mutual exclusion and unit limits

Mutual exclusionCodes 88187, 88188, and 88189 should not be used together for a single specimen in any combination.

Unit reimbursementCodes 88187, 88188, and 88189 are reimbursed at one unit per specimen, up to two specimens, per date of service.

Incompatibility with cell enumeration codesCodes 88187-88189 should not be used in conjunction with codes 86355, 86356, 86357, 86359, 86360, 86361, or 86367.

Provider Actions, Prior Auth, and Documentation

Prior Authorization

Prior Authorization Required

Prior authorization is required for the flow cytometry procedure codes listed in the policy. Submit requests with the clinical indication and relevant documentation (see Documentation callouts).

Submit prior authorization before services are rendered when required by the member's plan.
Include specimen type, clinical indication, and planned marker panel.
Attach prior laboratory results and pathology reports when available.

Denial Risk

Denial Risk — DNA Ploidy / S-Phase Fraction

Flow cytometry-derived DNA content (ploidy) or S-phase fraction (% S-phase) testing for routine prognostic or therapeutic management of cancers does not meet coverage criteria and is at high risk for denial.

Tests for DNA ploidy or S-phase fraction are considered investigational/unproven and will likely be denied.
Order only when clearly supported by coverage exceptions or applicable government policy (LCD/NCD).

Documentation Required

Clinical Indication and Coding Documentation

Specify the clinical indication and relevant diagnosis codes when ordering flow cytometry. Documentation must support medical necessity and the selected marker panel. Use reagent panel selection consistent with specimen type and clinical question.

Include the ICD-10 diagnosis and a brief clinical rationale on the order.
If testing is for an established neoplasm, limit markers to diagnostically relevant antigens.
For initial panels, document specimen type and reason for chosen initial reagents.
If a secondary panel is ordered, document why the initial panel was inconclusive and list additional markers requested.

Documentation Required

Transfer and Result Documentation

When referring patients or transferring care, send all prior laboratory results, pathology slides/reports, and flow cytometry data to the receiving center. Pending results should be forwarded when available.

Include prior flow cytometry reports and raw data files if available to avoid unnecessary repeat testing.
Provide cytogenetic and molecular test results and any pending test list at time of transfer.
Document transmission of prior results in the medical record and include them with prior authorization submission when applicable.

Billing Rule

Coding and Unit-Limit Requirements

Provider billing and coding must follow the specified CPT/HCPCS usage and unit limits. Use CPT 88184 for the first marker (up to 2 units per date of service), 88185 for additional markers (up to 35 units per date of service). Codes 88187–88189 are limited to one unit per specimen (up to two specimens per date of service) and must not be used together for a single specimen. Use 86355/86357/86359/86360/86361/86367 for cell enumeration (single unit only).

88184: first marker, technical component only; reimbursable up to 2 units per date of service.
88185: each additional marker; reimbursable up to 35 units per date of service.
88187/88188/88189: interpretation codes — one unit per specimen, up to two specimens per date of service; do not bill 88187, 88188, and 88189 together for the same specimen.
Do not report 88187–88189 with 86355, 86356, 86357, 86359, 86360, 86361, or 86367.
Use 86355, 86357, 86359, 86360, 86361, or 86367 for cell enumeration; these are single-unit codes only.

Ordering Requirements and Sample Handling

Billing Rule

ORDERING REQUIREMENTS — indication, coding, and unit limits

Order flow cytometry immunophenotyping with a specific clinical indication documented on the requisition, choose the appropriate CPT codes per the policy, and observe unit limits and mutually exclusive code combinations described in the coding section.

Document the clinical indication on the order
Use 88184 for first marker and 88185 for additional markers with the specified unit limits
Avoid prohibited code combinations (e.g., 88187–88189 with 86355–86367)

Note

ORDERING REQUIREMENTS — reagent selection and sample sufficiency

Select reagent panels based on specimen type, clinical information, and morphology; ensure sufficient sample collection to permit flow cytometry and any required concurrent testing (cytogenetics, molecular/FISH).

Choose reagents appropriate to specimen (peripheral blood, bone marrow, tissue) and clinical question
Obtain sufficient material for flow cytometry plus cytogenetic and molecular testing when indicated

Frequency and Unit Limits

inv-29: Flow cytometry immunophenotyping (CPT 88184-88189) and cell enumeration (86355-86367) — unit limits per date of service

ScopeApplies to flow cytometry immunophenotyping CPTs (88184-88189) and cell enumeration codes (86355-86367).

Unit limits — 88184CPT 88184 (first marker per specimen) reimbursable up to 2 units per date of service.

Unit limits — 88185CPT 88185 (each additional marker) reimbursable up to 35 units per date of service.

Unit limits — 88187-8818988187–88189 reimbursed 1 unit per specimen, up to 2 specimens per date of service; not used with cell enumeration codes listed.

Cell enumeration codesUse 86355, 86357, 86359, 86360, 86361, or 86367 for cell enumeration; these are reimbursable as single units only.

inv-30: No explicit frequency limits specified in this portion of the document.

Frequency limits statedNo explicit frequency limits are specified in this portion of the document for repeat testing; unit limits are defined per date of service but no separate time-based frequency rules are provided.

Panel sequencing noteGuidance focuses on initial and secondary reagent panels rather than stepwise frequency restrictions.

Ordering implicationClinicians should follow unit limits per date of service and document clinical indication; no additional frequency cap is described here.

Definitions

inv-23: SPF (S-phase fraction) definition

DefinitionSPF (S-phase fraction) = assessment of the percentage of cells actively synthesizing DNA; used as a measure of proliferative activity in neoplasms.

Clinical useProposed as a proliferation marker for prognostic assessment in some cancers, but evidence is inconsistent and routine use is not covered for prognostic/therapeutic management.

Method contextSPF is derived from flow cytometric analysis of DNA content in single cells.

inv-24: FCM / FCI — Flow cytometry / flow cytometric immunophenotyping definition

DefinitionFCM / FCI = Flow cytometry / flow cytometric immunophenotyping — identification of cell-surface or intracellular markers using flow cytometry.

ApplicationsUsed for immunophenotypic analysis to evaluate hematolymphoid neoplasia, immune monitoring (e.g., HIV), transplant monitoring, and cell enumeration.

Related codesImmunophenotyping reported with CPT codes 88184–88189; cell enumeration uses codes 86355–86367.

inv-25: Initial evaluation (flow cytometry) — definition

DefinitionInitial evaluation (flow cytometry) = the first-line reagent panel selected based on specimen type, clinical information, and cell morphology to identify or characterize suspected hematolymphoid neoplasia.

Panel sizeInitial evaluation panels identified in Bethesda range from 4 to 12 reagents depending on indication.

Panel examplesExample initial panels include B-cell (CD5, CD10, CD19, CD20, CD45, kappa, lambda), T-cell/NK (CD2, CD3, CD4, CD5, CD7, CD8, CD45, CD56), myelomonocytic, and plasma cell panels.

inv-26: Secondary evaluation (flow cytometry) — definition

DefinitionSecondary evaluation (flow cytometry) = follow-up reagent groups used when the initial evaluation is inconclusive or not informative; reagent selection is indication-specific.

Panel sizeSecondary evaluation panels range from 5 to 23 reagents per the Bethesda recommendations.

PurposeDesigned to further characterize immunophenotype, resolve diagnostic uncertainty, or expand marker testing based on initial panel findings.

OpenPayer